CaRe high

• Verfasst von: Schmidt, Nina [VerfasserIn]
• Verfasst von: Grammer, Tanja B. [VerfasserIn]
• Verfasst von: März, Winfried [VerfasserIn]
• Titel: CaRe high
• Titelzusatz: cascade screening and registry for high cholesterol in Germany
• Verf.angabe: Nina Schmidt, Tanja Grammer, Ioanna Gouni-Berthold, Ulrich Julius, Ursula Kassner, Gerald Klose, Christel König, Ulrich Laufs, Britta Otte, Elisabeth Steinhagen-Thiessen, Christoph Wanner, Winfried März
• E-Jahr: 2017
• Jahr: 1 June 2017
• Umfang: 5 S.
• Fussnoten: Available online 1 June 2017 ; Gesehen am 05.07.2018
• Titel Quelle: Enthalten in: Atherosclerosis. Supplements
• Ort Quelle: Amsterdam [u.a.] : Elsevier Science, 2000
• Jahr Quelle: 2017
• Band/Heft Quelle: 30(2017), Seite 72-76
• ISSN Quelle: 1878-5050
• DOI: doi:10.1016/j.atherosclerosissup.2017.05.015
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: Cardiovascular disease
• Sach-SW: Cascade screening
• Sach-SW: Familial hypercholesterolemia
• Sach-SW: Patient registry
• K10plus-PPN: 157733258X

Abstract

Introduction: Familial hypercholesterolemia (FH) is an inherited disorder of the LDL metabolism, leading to cardiovascular disease, even at young age. This risk can be significantly lowered by early diagnosis and treatment. About 270,000 patients affected in Germany are not diagnosed correctly and only a small number is treated properly. To improve FH diagnosis in the general population a cascade screening and registry data is warranted, yet missing in Germany. This project aims to fill this gap. Methods: Study assistants approach physicians and lipid clinics to introduce the cascade screening and registry. The physicians identify potential FH patients and include them in the study. Patient data is acquired via questionnaires about medical history. Patients meeting at least two inclusion criteria (LDL-C >190 mg/dl or total cholesterol >290 mg/dl; tendon xanthomas; family history of hypercholesterolemia or early myocardial infarction) are included in the registry. Family members will be contacted and physicians get feedback about diagnosis and treatment options. Ethical approvals for all German states have been collected. Results: So far physicians, lipid clinics and patients within the Rhein-Neckar region, the Saarland, North-Rhine-Westphalia, Upper Bavaria, Bremen, Saxonia and Berlin have joined the study. We expect to include more than 3000 patients during the next two years. Conclusion: After initial patient and data collection the project aims to improve FH-diagnosis and treatment. Utilizing registry data might advance diagnostic criteria and improve detection of FH and thus prevent CVD in this population.